NCT02254720View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of BEA 2180 BR in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

December 31, 2006

Conditions
Healthy
Interventions
DRUG

BEA 2180 BR solution for infusion

DRUG

Placebo

Intravenous infusion

DRUG

BEA 2180 BR solution for inhalation

DEVICE

Respimat®

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02254720 - Safety, Tolerability and Pharmacokinetics of BEA 2180 BR in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter